# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Deutsche Bank analyst Emmanuel Papadakis upgrades Moderna (NASDAQ:MRNA) from Sell to Hold and lowers the price target from $...
https://www.axios.com/2024/08/05/mpox-who-warning-africaThe World Health Organization is weighing discussions on whether to dec...
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID...
RBC Capital analyst Luca Issi downgrades Moderna (NASDAQ:MRNA) from Outperform to Sector Perform and lowers the price target...
12 worst-performing large-cap stocks in the last week. Symbotic, Intel, Snap, Moderna, Mobileye, Pinterest, Arm, Entegris, Atla...
RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Outperform and lowers the price target from $160 to $125.